Nevro Corp (NVRO):企業の財務・戦略的SWOT分析

◆英語タイトル:Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME7230FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥32,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥48,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Nevro Corp (NVRO) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nevro Corp (Nevro) is a medical device company which focuses on providing novel products that advance the quality of life of people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe and Australia. The company offers products under Senza, Senza II, Senza Omnia and the Nevro logo brands. Nevro is developing HF10 therapy for treating painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.

Nevro Corp Key Recent Developments

Apr 13,2021: Nevro to Present at BofA Securities 2021 Virtual Health Care Conference
Feb 24,2021: Nevro reports fourth quarter and full year 2020 financial results
Jan 11,2021: Nevro announces preliminary, unaudited fourth quarter and full-year 2020 revenue
Dec 14,2020: Boston Scientific announces stipulation of dismissal of Nevro Corporation’s patent infringement case in California
Dec 03,2020: Nevro announces director appointment

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Nevro Corp – Key Facts
Nevro Corp – Key Employees
Nevro Corp – Key Employee Biographies
Nevro Corp – Major Products and Services
Nevro Corp – History
Nevro Corp – Company Statement
Nevro Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Nevro Corp – Business Description
Geographical Segment: International
Target Markets
Performance
Geographical Segment: The US
Performance
R&D Overview
Nevro Corp – Corporate Strategy
Nevro Corp – SWOT Analysis
SWOT Analysis – Overview
Nevro Corp – Strengths
Nevro Corp – Weaknesses
Nevro Corp – Opportunities
Nevro Corp – Threats
Nevro Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Nevro Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Nevro Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Nevro Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 13, 2021: Nevro to Present at BofA Securities 2021 Virtual Health Care Conference
Feb 24, 2021: Nevro reports fourth quarter and full year 2020 financial results
Jan 11, 2021: Nevro announces preliminary, unaudited fourth quarter and full-year 2020 revenue
Dec 14, 2020: Boston Scientific announces stipulation of dismissal of Nevro Corporation’s patent infringement case in California
Dec 03, 2020: Nevro announces director appointment
Nov 30, 2020: Nevro appoints Julie D. Dewey as vice president, investor relations and corporate communications
Nov 05, 2020: Nevro announces third quarter 2020 financial results
Sep 14, 2020: Nevro initiates plan for manufacturing operations in Costa Rica to support future growth
Aug 05, 2020: Nevro announces second quarter 2020 financial results
Jun 04, 2020: Nevro appoints finance executive Roderick MacLeod as Chief Financial Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Nevro Corp, Key Facts
Nevro Corp, Key Employees
Nevro Corp, Key Employee Biographies
Nevro Corp, Major Products and Services
Nevro Corp, History
Nevro Corp, Subsidiaries
Nevro Corp, Key Competitors
Nevro Corp, Ratios based on current share price
Nevro Corp, Annual Ratios
Nevro Corp, Annual Ratios (Cont...1)
Nevro Corp, Interim Ratios
Nevro Corp, Medical Equipment, Deals By Year, 2015 to YTD 2021
Nevro Corp, Medical Equipment, Deals By Type, 2015 to YTD 2021
Nevro Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Nevro Corp (NVRO):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Clearside BioMedical Inc (CLSD):医療機器:M&Aディール及び事業提携情報
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • China Resources Land Limited:戦略・SWOT・企業財務分析
    China Resources Land Limited - Strategy, SWOT and Corporate Finance Report Summary China Resources Land Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Centrica Plc (CNA):石油・ガス:M&Aディール及び事業提携情報
    Summary Centrica Plc (Centrica) is an integrated energy company. It carries out electricity generation through and combined cycle gas turbine (CCGT) power stations, and nuclear power plants through its stake in EDF Energy Nuclear Generation. Centrica secures and supply gas and electricity to homes a …
  • American Dental Partners Inc:企業の戦略的SWOT分析
    American Dental Partners Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Henry Lamotte Group:戦略・SWOT・企業財務分析
    Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report Summary Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Teijin Limited:戦略・SWOT・企業財務分析
    Teijin Limited - Strategy, SWOT and Corporate Finance Report Summary Teijin Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • GATX Corp (GATX):企業の財務・戦略的SWOT分析
    GATX Corp (GATX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Centene Corp (CNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Centene Corp (Centene) is a healthcare service provider that offers services to government sponsored healthcare programs with focus on under-insured and uninsured individuals. It provides health plans through Medicaid, Medicare and Health Insurance Marketplace contracts; and other health sol …
  • mixi, Inc.:企業の戦略・SWOT・財務分析
    mixi, Inc. - Strategy, SWOT and Corporate Finance Report Summary mixi, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Xcel Energy Inc:企業の発電所・SWOT分析2018
    Xcel Energy Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (ex …
  • Robert Bosch GmbH:企業の戦略・SWOT・財務分析
    Robert Bosch GmbH - Strategy, SWOT and Corporate Finance Report Summary Robert Bosch GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Xvivo Perfusion AB (XVIVO):企業の財務・戦略的SWOT分析
    Summary Xvivo Perfusion AB (Xvivo) is a medical technology company that provides organ transplantation solutions. The company develops organ preservation products such as perfadex and silicone tubing sets and normothermic perfusion products. It offers normothermic perfusion products such as STEEN so …
  • PerkinElmer Inc (PKI):企業の製品パイプライン分析
    Summary PerkinElmer Inc (PerkinElmer) is a provider of detection and imaging technologies, consumables, informatics solutions, accessories and services. The company’s major products include cytogenetics reagents, ELISA Kits, tissue biomarker reagents, atomic spectroscopy instruments, chromatography …
  • Nayara Energy Ltd:企業の戦略的SWOT分析
    Nayara Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • FDM Group (Holdings) plc (FDM):企業の財務・戦略的SWOT分析
    FDM Group (Holdings) plc (FDM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Albany Molecular Research Inc-製薬・医療分野:企業M&A・提携分析
    Summary Albany Molecular Research Inc (AMRI) is a contract research and manufacturing organization. Its service portfolio drug discovery and development, manufacturing of Active Pharmaceutical Ingredients (API); process scale up development of fine chemicals and aseptic filling services for preclini …
  • Caixa Geral de Depositos SA:企業の戦略的SWOT分析
    Caixa Geral de Depositos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • DURECT Corp (DRRX):企業の財務・戦略的SWOT分析
    DURECT Corp (DRRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析
    Summary SciClone Pharmaceuticals Inc (SciClone) develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin), an immunostimulatory agent approved for the treatment of hepatitis B virus (HBV), hep …
  • Neoen SAS:電力:M&Aディール及び事業提携情報
    Summary Neoen SAS (Neoen), a subsidiary of Direct Energie SA, is an independent producer of sustainable energy provider. The company generates power from solar, wind and biomass. It specializes in the development, finance, construction and operation of green power plants such as wind farms, solar fa …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆